STOCK TITAN

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Nanobiotix, a late-clinical stage biotechnology company, announced that its co-founder and chairman, Laurent Levy, and CFO, Bart Van Rhijn, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024. The chat will be webcast live and a replay will be available on the company's website.
Positive
  • None.
Negative
  • None.

PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024, at 3:00 PM ET / 9:00 PM CET in New York, NY.

The fireside chat will be webcast live from the events page of the Investors section of the Company’s website. A replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in, among other, Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 20 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix 

Communications Department

Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com


Investor Relations Department

Craig West
SVP, Investor Relations
+1 (617) 583-0211
investors@nanobiotix.com

 
Media Relations 

FR – Ulysse Communication
Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com


Global – LifeSci Advisors
Kevin Gardner
+1 (617) 283-2856
kgardner@lifesciadvisors.com

 

 

Attachment


FAQ

When and where will Nanobiotix's fireside chat take place?

Nanobiotix's fireside chat will take place at the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024, at 3:00 PM ET / 9:00 PM CET in New York, NY.

Who will participate in Nanobiotix's fireside chat?

Laurent Levy, co-founder and chairman of Nanobiotix, and Bart Van Rhijn, chief financial officer, will participate in the fireside chat.

Where can I watch the webcast of Nanobiotix's fireside chat?

The webcast of Nanobiotix's fireside chat will be available on the events page of the Investors section of the Company’s website.

Will there be a replay of Nanobiotix's fireside chat available?

Yes, a replay of the webcast will be available following the event.

Nanobiotix S.A.

NASDAQ:NBTX

NBTX Rankings

NBTX Latest News

NBTX Stock Data

344.38M
20.76M
19.68%
0.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Paris

About NBTX

nanobiotix (euronext: nano / isin: fr0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. the company’s first-in-class, proprietary technology, nanoxray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients. nanoxray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. nbtxr3 is being evaluated in: soft tissue sarcoma (sts), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). additionally, head and neck cancer and rectal cancer trials led by nanobiotix’s taiwanese partner, pharmaengine, are underway in the asia pacific region. the company started a new preclinical research program in immuno-oncology with its lea